NCT04654897View on ClinicalTrials.gov

Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

October 29, 2020

Study Completion Date

October 29, 2020

Conditions
Healthy
Interventions
DRUG

[14C]-NT-814

120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Bayer

INDUSTRY